- Home
- Media Center
- Press releases
- Innovative Medicine
Innovative Medicine
Janssen Announces TREMFYA® (guselkumab) Demonstrates Significant Skin Clearance in First-of-its-Kind Prospective, Large-Scale Study Dedicated to People of Color Living with Moderate to Severe Plaque Psoriasis
VISIBLE Cohort A Week 16 topline results achieve co-primary endpoints, demonstrating the well-established efficacy and safety profile of TREMFYA® across all skin tones In additional datasets, TREMFYA® demonstrated rapid and significant scalp psoriasis clearance and improved key health-related quality of life outcomes VISIBLE aims to generate an expansive longitudinal collection of PsO clinical images across skin tones and novel post-inflammatory pigmentation data to assist providers in helping patients better understand the diagnosis and treatment journey
Janssen Announces Promising Antiviral Activity Against Dengue in a Phase 2a Human Challenge Model
The antiviral JNJ-1802 induced prophylactic antiviral activity against dengue in a human challenge model Dengue infects millions of people annually and could impact many more as climate change fuels outbreaks The antiviral, previously found to be safe and well-tolerated, is now in a community-based field study to establish efficacy in a real-world setting
TREMFYA® (guselkumab) Maintains Key Efficacy Endpoints Through Three Years for Adults with Moderately to Severely Active Crohn’s Disease in a Phase 2 Study
Key efficacy endpoints of the long-term extension GALAXI study included clinical remission, patient-reported outcome remission, and endoscopic response
Janssen to Highlight Latest Research from Nipocalimab Clinical Development Program to Address Unmet Need in Myasthenia Gravis at AANEM 2023 Meeting
Data presentations reinforce potential for rapid, deep, and sustained efficacy with treatment and demonstrate how the unique immuno-selectivity of the compound may allow for greater targeting across a wide range of autoantibody-driven diseases
Janssen Aims to Define New Standards of Care in the Treatment of Solid Tumor Cancers with Transformative Data Planned for Presentation at ESMO
Three Phase 3 RYBREVANT® (amivantamab-vmjw) studies (MARIPOSA, MARIPOSA-2 and PAPILLON) in EGFR-mutated lung cancer achieved statistically significant and clinically meaningful progression-free survival endpoints and will be presented in Presidential Symposium sessions New results for investigational TAR-200 and TAR-210 novel intravesical delivery system highlight potential for transformational outcomes in the treatment of bladder cancer
Janssen Highlights Latest Research for TREMFYA® (guselkumab) and Investigational Targeted Oral Peptide JNJ-2113 in Moderate to Severe Plaque Psoriasis at the European Academy of Dermatology and Venereology (EADV) Congress
30 presentations showcase breadth of data from Janssen’s Immunodermatology pipeline across five commercialized and investigational therapies
Janssen Submits Application to the European Medicines Agency for RYBREVANT®▼ (amivantamab) in Combination with Chemotherapy for the First-Line Treatment of Adult Patients with Advanced Non-Small Cell Lung Cancer with Activating EGFR Exon 20 Insertion Mutations
Type II Extension of Indication Application is supported by data from PAPILLON, the first randomised Phase 3 study to read out in patients with NSCLC with EGFR exon 20 insertion mutations1
SPRAVATO® (esketamine) Demonstrates Superior Efficacy Compared to Quetiapine Extended-Release in Treatment-Resistant Major Depressive Disorder
Data Published in the Current Issue of New England Journal of Medicine.
Janssen to Highlight Latest Advances in Retina Portfolio at the European Society of Retina Specialists (EURETINA) 2023 Annual Meeting
Five abstracts to be presented, including new real-world research and data on Janssen’s investigational gene therapy JNJ-1887